Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation.
Atsuta Y, Sugita J, Nakamae H, Maruyama Y, Ishiyama K, Shiratori S, Fukuda T, Kurata M, Shingai N, Ozawa Y, Masuko M, Nagafuji K, Takada S, Kako S, Kanda Y, Kanda J, Ichinohe T, Teshima T. Atsuta Y, et al. Among authors: maruyama y. Bone Marrow Transplant. 2022 Dec;57(12):1781-1787. doi: 10.1038/s41409-022-01822-3. Epub 2022 Sep 12. Bone Marrow Transplant. 2022. PMID: 36097040
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Shimomura Y, Hara M, Yamamoto H, Uchida N, Kawakita T, Ashida T, Takada S, Ikeda T, Morishige S, Maruyama Y, Wake A, Ichinohe T, Fukuda T, Takanashi M, Atsuta Y, Ishikawa T. Shimomura Y, et al. Among authors: maruyama y. Bone Marrow Transplant. 2021 Jul;56(7):1691-1699. doi: 10.1038/s41409-021-01217-w. Epub 2021 Mar 3. Bone Marrow Transplant. 2021. PMID: 33658646
Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T, Kanda J, Yamasaki S, Harada K, Shimomura Y, Terakura S, Mizuno S, Uchida N, Tanaka M, Doki N, Ozawa Y, Nakamae H, Sawa M, Matsuoka KI, Morishige S, Maruyama Y, Ikegame K, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yanada M. Konuma T, et al. Among authors: maruyama y. Transplant Cell Ther. 2021 Apr;27(4):334.e1-334.e11. doi: 10.1016/j.jtct.2021.01.023. Epub 2021 Jan 28. Transplant Cell Ther. 2021. PMID: 33836881 Free article.
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
Shimomura Y, Hara M, Hirabayashi S, Kondo T, Mizuno S, Uchida N, Mukae J, Kawakita T, Fukuda T, Kanda Y, Ota S, Ozawa Y, Eto T, Maruyama Y, Tanaka M, Nakano N, Kimura T, Ichinohe T, Atsuta Y, Yanada M. Shimomura Y, et al. Among authors: maruyama y. Bone Marrow Transplant. 2021 Sep;56(9):2302-2304. doi: 10.1038/s41409-021-01380-0. Epub 2021 Jun 21. Bone Marrow Transplant. 2021. PMID: 34155357 No abstract available.
Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
Yanada M, Mizuno S, Yamasaki S, Harada K, Konuma T, Tamaki H, Shingai N, Uchida N, Ozawa Y, Tanaka M, Onizuka M, Sawa M, Nakamae H, Shiratori S, Matsuoka KI, Eto T, Kawakita T, Maruyama Y, Ichinohe T, Kanda Y, Atsuta Y, Aoki J, Yano S. Yanada M, et al. Among authors: maruyama y. Leuk Lymphoma. 2021 Dec;62(14):3411-3419. doi: 10.1080/10428194.2021.1961242. Epub 2021 Aug 4. Leuk Lymphoma. 2021. PMID: 34348554
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kanda J, Fukuda T, Atsuta Y, Aoki J. Kurosawa S, et al. Among authors: maruyama y. Bone Marrow Transplant. 2021 Dec;56(12):3008-3015. doi: 10.1038/s41409-021-01447-y. Epub 2021 Sep 7. Bone Marrow Transplant. 2021. PMID: 34489555
Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.
Yokoyama H, Hirayama M, Takahashi Y, Uchida N, Tanaka M, Onizuka M, Ozawa Y, Onai D, Katsuoka Y, Wake A, Sawa M, Kobayashi H, Maruyama Y, Ozeki K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Terakura S, Morishima S. Yokoyama H, et al. Among authors: maruyama y. Bone Marrow Transplant. 2021 Dec;56(12):3059-3067. doi: 10.1038/s41409-021-01469-6. Epub 2021 Sep 24. Bone Marrow Transplant. 2021. PMID: 34561558
Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT.
Inoue T, Koyama M, Kaida K, Ikegame K, Ensbey KS, Samson L, Takahashi S, Zhang P, Minnie SA, Maruyama S, Ishii S, Daimon T, Fukuda T, Nakamae H, Ara T, Maruyama Y, Ishiyama K, Ichinohe T, Atsuta Y, Blazar BR, Furlan SN, Ogawa H, Hill GR. Inoue T, et al. Among authors: maruyama s, maruyama y. JCI Insight. 2021 Nov 22;6(22):e153551. doi: 10.1172/jci.insight.153551. JCI Insight. 2021. PMID: 34637399 Free PMC article.
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. Kurosawa S, et al. Among authors: maruyama y. Transplant Cell Ther. 2022 Jun;28(6):323.e1-323.e9. doi: 10.1016/j.jtct.2022.03.011. Epub 2022 Mar 13. Transplant Cell Ther. 2022. PMID: 35296446 Free article.
Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Harada K, Morita-Fujita M, Fukuda T, Ozawa Y, Doki N, Toyosaki M, Maruyama Y, Kanda Y, Ashida T, Eto T, Takada S, Uchida N, Ichinohe T, Kanda J, Onizuka M, Atsuta Y, Kako S, Arai Y. Harada K, et al. Among authors: maruyama y. Cytotherapy. 2022 Sep;24(9):954-961. doi: 10.1016/j.jcyt.2022.03.004. Epub 2022 May 7. Cytotherapy. 2022. PMID: 35534419 Free article.
2,409 results